Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$418.91 USD
-0.65 (-0.15%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $419.04 +0.13 (0.03%) 4:40 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Alnylam Pharmaceuticals, Inc.'s return on equity, or ROE, is -273.52% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that ALNY has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ALNY 418.91 -0.65(-0.15%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Other News for ALNY
Alnylam Pharmaceuticals Inc (ALNY) to Present at Canaccord Genuity 45th Annual Growth ...
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference | ALNY Stock News
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls
Oppenheimer Upgrades Alnylam Pharmaceuticals (ALNY) with New Price Target | ALNY Stock News